Literature DB >> 24890437

Epidermolysis bullosa acquisita: a retrospective analysis of 12 patients evaluated in four tertiary hospitals in Spain.

P Iranzo1, J E Herrero-González, J M Mascaró-Galy, R Suárez-Fernández, A España.   

Abstract

BACKGROUND: Epidermolysis bullosa acquisita is an exceedingly rare subepidermal blistering disease caused by antibodies against type VII collagen. Studies summarizing the clinical and immunological features of this disease in large series of patients are scarce.
OBJECTIVES: To analyse the clinical and immunopathological characteristics, treatment responses and outcomes of 12 patients with epidermolysis bullosa acquisita from four tertiary hospitals in Spain.
METHODS: An extensive retrospective review of clinical charts.
RESULTS: The mean age of onset was 48 years and the mean delay to diagnosis was 20·75 months. The classical phenotype occurred in 42% of cases, inflammatory in 42% and mixed in 17%. Mucosal involvement was present in 75%. Linear IgG deposition along the basement membrane zone was consistently present on direct immunofluorescence examination. Indirect immunofluorescence study was positive in 67% of the cases. Frequently associated diseases were neoplasms (25%), inflammatory bowel disease (25%), hepatitis C virus infection (17%) and thyroid dysfunction (17%). Therapeutic responses were variable.
CONCLUSIONS: The prevalence of neoplasms was similar to that seen in inflammatory bowel disease. Multicentric prospective studies including larger numbers of patients are required for a better knowledge and management of this disease.
© 2014 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24890437     DOI: 10.1111/bjd.13144

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  9 in total

Review 1.  Mechanisms of Autoantibody-Induced Pathology.

Authors:  Ralf J Ludwig; Karen Vanhoorelbeke; Frank Leypoldt; Ziya Kaya; Katja Bieber; Sandra M McLachlan; Lars Komorowski; Jie Luo; Otavio Cabral-Marques; Christoph M Hammers; Jon M Lindstrom; Peter Lamprecht; Andrea Fischer; Gabriela Riemekasten; Claudia Tersteeg; Peter Sondermann; Basil Rapoport; Klaus-Peter Wandinger; Christian Probst; Asmaa El Beidaq; Enno Schmidt; Alan Verkman; Rudolf A Manz; Falk Nimmerjahn
Journal:  Front Immunol       Date:  2017-05-31       Impact factor: 7.561

2.  Epidermolysis bullosa acquisita.

Authors:  Denise Miyamoto; Juliana Olivieri Gordilho; Claudia Giuli Santi; Adriana Maria Porro
Journal:  An Bras Dermatol       Date:  2022-06-11       Impact factor: 2.113

Review 3.  Cutaneous Manifestations of Inflammatory Bowel Disease: A Basic Overview.

Authors:  Kyla Pagani; Danitza Lukac; Aashni Bhukhan; Jean S McGee
Journal:  Am J Clin Dermatol       Date:  2022-04-20       Impact factor: 6.233

Review 4.  Rituximab therapy in pemphigus and other autoantibody-mediated diseases.

Authors:  Nina A Ran; Aimee S Payne
Journal:  F1000Res       Date:  2017-01-27

5.  Histologic characterization of cellular infiltration in autoimmune subepidermal bullous diseases in a tertiary hospital in Saudi Arabia.

Authors:  Hessah F BinJadeed; Alanoud M Alyousef; Fahad M Alsaif; Ahmed A Alhumidi; Homaid O Alotaibi
Journal:  Clin Cosmet Investig Dermatol       Date:  2018-04-24

6.  Steroid-induced Diabetes Complicating Treatment of Epidermolysis Bullosa Acquisita: A Preventable Treatment Complication Stresses the Importance of Primary Care Follow-up.

Authors:  Victoria Byrd; Attila Nemeth
Journal:  Cureus       Date:  2018-11-19

7.  Epidermolysis Bullosa Acquisita: A Case Report of a Rare Clinical Phenotype and a Review of Literature.

Authors:  Cristina Beiu; Mara Mihai; Liliana Popa; Tiberiu Tebeica; Calin Giurcaneanu
Journal:  Cureus       Date:  2019-12-15

8.  An 81-Year-Old Woman with Recalcitrant Blisters.

Authors:  Daniel C Butler
Journal:  Dermatopathology (Basel)       Date:  2018-01-11

Review 9.  Epidermolysis Bullosa Acquisita: The 2019 Update.

Authors:  Hiroshi Koga; Catherine Prost-Squarcioni; Hiroaki Iwata; Marcel F Jonkman; Ralf J Ludwig; Katja Bieber
Journal:  Front Med (Lausanne)       Date:  2019-01-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.